Merck/Schering's Vytorin Priced At 22% Discount To Pfizer's Lipitor
This article was originally published in The Pink Sheet Daily
Executive Summary
The ezetimibe/simvastatin combination is priced at a 39% discount to the three highest doses of Merck's Zocor. Vytorin will launch in August at a wholesale acquisition cost of $2.34 per day.
You may also be interested in...
Merck Tallies Vytorin Switches: 27% From Zocor, 24% From Lipitor
Combined Vytorin and Zetia new prescription share is now 11%, with total prescription share at 10%, Merck reports. Global sales for the drugs were $511 mil. in the first quarter, with $332 mil. from Zetia and $179 mil. from Vytorin.
Merck Tallies Vytorin Switches: 27% From Zocor, 24% From Lipitor
Combined Vytorin and Zetia new prescription share is now 11%, with total prescription share at 10%, Merck reports. Global sales for the drugs were $511 mil. in the first quarter, with $332 mil. from Zetia and $179 mil. from Vytorin.
Merck Cholesterol Franchise Will Decline In 2005
Merck predicts that Zocor franchise will lose about $750 mil. in sales during 2005, primarily due to European patent expirations. That will be partially offset by approximately $450 mil. in new income from Vytorin and Zetia through the joint venture with Schering-Plough.